

## SPECIALTY GUIDELINE MANAGEMENT

### ELIGARD (leuprolide acetate)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indication

Palliative treatment of advanced prostate cancer

###### B. Compendial Uses

1. Prostate cancer
2. Recurrent androgen receptor positive salivary gland tumors
3. Gender Dysphoria (also known as gender non-conforming or transgender persons)

All other indications are considered experimental/investigational and not medically necessary.

##### II. PRESCRIBER SPECIALTIES

For gender dysphoria, the medication must be prescribed by or in consultation with a provider specialized in the care of transgender youth (e.g., pediatric endocrinologist, family or internal medicine physician, obstetrician-gynecologist) that has collaborated care with a mental health provider for patients less than 18 years of age.

##### III. CRITERIA FOR INITIAL APPROVAL

###### A. **Prostate cancer**

Authorization of 12 months may be granted for treatment of prostate cancer.

###### B. **Gender dysphoria**

1. Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member when all of the following criteria are met:
  - i. The member has a diagnosis of gender dysphoria.
  - ii. The member has reached Tanner stage 2 of puberty or greater.
  - iii. The member's comorbid conditions are reasonably controlled.
  - iv. The member has been educated on any contraindications and side effects to therapy.
  - v. The member has been informed of fertility preservation options.
2. Authorization of 12 months may be granted for gender transition when all of the following criteria are met:
  - i. The member has a diagnosis of gender dysphoria.
  - ii. The member will receive Eligard concomitantly with gender-affirming hormones.
  - iii. The member's comorbid conditions are reasonably controlled.

Reference number(s)
1966-A

- iv. The member has been educated on any contraindications and side effects to therapy.
- v. The member has been informed of fertility preservation options.

#### C. Salivary gland tumors

Authorization of 12 months may be granted for treatment of recurrent salivary gland tumors as a single agent when the tumor is androgen receptor positive.

### IV. CONTINUATION OF THERAPY

#### A. Salivary gland tumors

Authorization of 12 months may be granted for continued treatment of salivary gland tumors in members requesting reauthorization who are experiencing clinical benefit to therapy and who have not experienced an unacceptable toxicity.

#### B. Prostate cancer

Authorization of 12 months may be granted for continued treatment of prostate cancer in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL) and who have not experienced an unacceptable toxicity.

#### C. Gender Dysphoria

1. Authorization of 12 months may be granted for continued treatment for pubertal hormonal suppression in adolescent members requesting reauthorization when all of the following criteria are met:
  - i. The member has a diagnosis of gender dysphoria.
  - ii. The member has previously reached Tanner stage 2 of puberty or greater.
  - iii. The member's comorbid conditions are reasonably controlled.
  - iv. The member has been educated on any contraindications and side effects to therapy.
  - v. Before the start of therapy, the member has been informed of fertility preservation options.
2. Authorization of 12 months may be granted for continued treatment for gender transition in members requesting reauthorization when all of the following criteria are met:
  - i. The member has a diagnosis of gender dysphoria.
  - ii. The member will receive Eligard concomitantly with gender-affirming hormones.
  - iii. The member's comorbid conditions are reasonably controlled.
  - iv. The member has been educated on any contraindications and side effects to therapy.
  - v. Before the start of therapy, the member has been informed of fertility preservation options.

### V. REFERENCES

1. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals; April 2019.
2. The NCCN Drugs & Biologics Compendium® © 2022 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 1, 2022.
3. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869–3903.
4. Gender Identity Research and Education Society. Guidance for GPs and other clinicians on the treatment of gender variant people. UK Department of Health. Published March 10, 2008.
5. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, 7th version. ©2012 World Professional Association for Transgender Health. Available at <http://www.wpath.org>.
6. Clinical Consult: CVS Caremark Clinical Programs Review. Focus on Gender Dysphoria Clinical Programs. July 2020.

Reference number(s)
1966-A

7. Mahfouda S, Moore JK, Siafarikas A, et al. Puberty Suppression in Transgender Children and Adolescents. *Lancet Diabetes Endocrinol*. 2017; 5: 816-26.
8. Health Care for Transgender and Gender Diverse Individuals. ©2021 The American College of Obstetricians and Gynecologists. Available at: <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/03/health-care-for-transgender-and-gender-diverse-individuals>.
9. Clinical Consult: CVS Caremark Clinical Programs Review. Focus on Gender Dysphoria Clinical Programs. September 2022.